Global CAR T-Cell-Based Drug market size is predicted to grow from US$ 6394 million in 2025 to US$ 31580 million in 2031; it is expected to grow at a CAGR of 30.5% from 2025 to 2031. Get Access Now!

Global CAR T-Cell-Based Drug Market Growth Status and Outlook 2025-2031

The global CAR T-Cell-Based Drug market size is predicted to grow from US$ 6394 million in 2025 to US$ 31580 million in 2031; it is expected to grow at a CAGR of 30.5% from 2025 to 2031. Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer. The CAR T-cell-based drug market is driven by the growing demand for innovative and targeted cancer therapies. Chimeric Antigen Receptor (CAR) T-cell therapy is a revolutionary approach that involves genetically modifying a patients T cells to recognize and attack cancer cells. The success of CAR T-cell therapies in treating certain types of blood cancers, such as leukemia and lymphoma, has fueled market growth and encouraged research into expanding the application of CAR T-cell therapy to other solid tumor malignancies. However, the market also faces challenges, including the high cost of CAR T-cell therapy and the complexity of the manufacturing process, which may limit patient access. Additionally, the potential for severe side effects and the need for patient selection and management pose regulatory and clinical challenges. To succeed, companies must focus on advancing research, streamlining the production process, collaborating with healthcare providers to improve patient access and support, and addressing safety and efficacy concerns to establish CAR T-cell-based drugs as a transformative treatment option for cancer patients. LPI (LP Information) newest research report, the CAR T-Cell-Based Drug Industry Forecast looks at past sales and reviews total world CAR T-Cell-Based Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected CAR T-Cell-Based Drug sales for 2025 through 2031. With CAR T-Cell-Based Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CAR T-Cell-Based Drug industry. This Insight Report provides a comprehensive analysis of the global CAR T-Cell-Based Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on CAR T-Cell-Based Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global CAR T-Cell-Based Drug market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CAR T-Cell-Based Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CAR T-Cell-Based Drug. This report presents a comprehensive overview, market shares, and growth opportunities of CAR T-Cell-Based Drug market by product type, application, key players and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; CD19-targeted &nbsp;&nbsp;&nbsp; BCMA-targeted Segmentation by Application: &nbsp;&nbsp;&nbsp; Lymphoma &nbsp;&nbsp;&nbsp; Multiple Myeloma This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Novartis &nbsp;&nbsp;&nbsp; Gilead Sciences &nbsp;&nbsp;&nbsp; Bristol-Myers Squibb &nbsp;&nbsp;&nbsp; J & J &nbsp;&nbsp;&nbsp; JW Therapeutics &nbsp;&nbsp;&nbsp; FOSUNKite &nbsp;&nbsp;&nbsp; CARsgen Therapeutics &nbsp;&nbsp;&nbsp; Autolus Therapeutics &nbsp;&nbsp;&nbsp; Sorrento Therapeutics &nbsp;&nbsp;&nbsp; Mustang Bio &nbsp;&nbsp;&nbsp; Bluebird Bio &nbsp;&nbsp;&nbsp; Cellectis &nbsp;&nbsp;&nbsp; Allogene Therapeutics &nbsp;&nbsp;&nbsp; Celyad

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global CAR T-Cell-Based Drug Market Size (2020-2031) &nbsp;2.1.2 CAR T-Cell-Based Drug Market Size CAGR by Region (2020 VS 2024 VS 2031) &nbsp;2.1.3 World Current & Future Analysis for CAR T-Cell-Based Drug by Country/Region (2020, 2024 & 2031) &nbsp;2.2 CAR T-Cell-Based Drug Segment by Type &nbsp;2.2.1 CD19-targeted &nbsp;2.2.2 BCMA-targeted &nbsp;2.3 CAR T-Cell-Based Drug Market Size by Type &nbsp;2.3.1 CAR T-Cell-Based Drug Market Size CAGR by Type (2020 VS 2024 VS 2031) &nbsp;2.3.2 Global CAR T-Cell-Based Drug Market Size Market Share by Type (2020-2025) &nbsp;2.4 CAR T-Cell-Based Drug Segment by Application &nbsp;2.4.1 Lymphoma &nbsp;2.4.2 Multiple Myeloma &nbsp;2.5 CAR T-Cell-Based Drug Market Size by Application &nbsp;2.5.1 CAR T-Cell-Based Drug Market Size CAGR by Application (2020 VS 2024 VS 2031) &nbsp;2.5.2 Global CAR T-Cell-Based Drug Market Size Market Share by Application (2020-2025) 3 CAR T-Cell-Based Drug Market Size by Player &nbsp;3.1 CAR T-Cell-Based Drug Market Size Market Share by Player &nbsp;3.1.1 Global CAR T-Cell-Based Drug Revenue by Player (2020-2025) &nbsp;3.1.2 Global CAR T-Cell-Based Drug Revenue Market Share by Player (2020-2025) &nbsp;3.2 Global CAR T-Cell-Based Drug Key Players Head office and Products Offered &nbsp;3.3 Market Concentration Rate Analysis &nbsp;3.3.1 Competition Landscape Analysis &nbsp;3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.4 New Products and Potential Entrants &nbsp;3.5 Mergers & Acquisitions, Expansion 4 CAR T-Cell-Based Drug by Region &nbsp;4.1 CAR T-Cell-Based Drug Market Size by Region (2020-2025) &nbsp;4.2 Global CAR T-Cell-Based Drug Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas CAR T-Cell-Based Drug Market Size Growth (2020-2025) &nbsp;4.4 APAC CAR T-Cell-Based Drug Market Size Growth (2020-2025) &nbsp;4.5 Europe CAR T-Cell-Based Drug Market Size Growth (2020-2025) &nbsp;4.6 Middle East & Africa CAR T-Cell-Based Drug Market Size Growth (2020-2025) 5 Americas &nbsp;5.1 Americas CAR T-Cell-Based Drug Market Size by Country (2020-2025) &nbsp;5.2 Americas CAR T-Cell-Based Drug Market Size by Type (2020-2025) &nbsp;5.3 Americas CAR T-Cell-Based Drug Market Size by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC CAR T-Cell-Based Drug Market Size by Region (2020-2025) &nbsp;6.2 APAC CAR T-Cell-Based Drug Market Size by Type (2020-2025) &nbsp;6.3 APAC CAR T-Cell-Based Drug Market Size by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia 7 Europe &nbsp;7.1 Europe CAR T-Cell-Based Drug Market Size by Country (2020-2025) &nbsp;7.2 Europe CAR T-Cell-Based Drug Market Size by Type (2020-2025) &nbsp;7.3 Europe CAR T-Cell-Based Drug Market Size by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa CAR T-Cell-Based Drug by Region (2020-2025) &nbsp;8.2 Middle East & Africa CAR T-Cell-Based Drug Market Size by Type (2020-2025) &nbsp;8.3 Middle East & Africa CAR T-Cell-Based Drug Market Size by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Global CAR T-Cell-Based Drug Market Forecast &nbsp;10.1 Global CAR T-Cell-Based Drug Forecast by Region (2026-2031) &nbsp;10.1.1 Global CAR T-Cell-Based Drug Forecast by Region (2026-2031) &nbsp;10.1.2 Americas CAR T-Cell-Based Drug Forecast &nbsp;10.1.3 APAC CAR T-Cell-Based Drug Forecast &nbsp;10.1.4 Europe CAR T-Cell-Based Drug Forecast &nbsp;10.1.5 Middle East & Africa CAR T-Cell-Based Drug Forecast &nbsp;10.2 Americas CAR T-Cell-Based Drug Forecast by Country (2026-2031) &nbsp;10.2.1 United States Market CAR T-Cell-Based Drug Forecast &nbsp;10.2.2 Canada Market CAR T-Cell-Based Drug Forecast &nbsp;10.2.3 Mexico Market CAR T-Cell-Based Drug Forecast &nbsp;10.2.4 Brazil Market CAR T-Cell-Based Drug Forecast &nbsp;10.3 APAC CAR T-Cell-Based Drug Forecast by Region (2026-2031) &nbsp;10.3.1 China CAR T-Cell-Based Drug Market Forecast &nbsp;10.3.2 Japan Market CAR T-Cell-Based Drug Forecast &nbsp;10.3.3 Korea Market CAR T-Cell-Based Drug Forecast &nbsp;10.3.4 Southeast Asia Market CAR T-Cell-Based Drug Forecast &nbsp;10.3.5 India Market CAR T-Cell-Based Drug Forecast &nbsp;10.3.6 Australia Market CAR T-Cell-Based Drug Forecast &nbsp;10.4 Europe CAR T-Cell-Based Drug Forecast by Country (2026-2031) &nbsp;10.4.1 Germany Market CAR T-Cell-Based Drug Forecast &nbsp;10.4.2 France Market CAR T-Cell-Based Drug Forecast &nbsp;10.4.3 UK Market CAR T-Cell-Based Drug Forecast &nbsp;10.4.4 Italy Market CAR T-Cell-Based Drug Forecast &nbsp;10.4.5 Russia Market CAR T-Cell-Based Drug Forecast &nbsp;10.5 Middle East & Africa CAR T-Cell-Based Drug Forecast by Region (2026-2031) &nbsp;10.5.1 Egypt Market CAR T-Cell-Based Drug Forecast &nbsp;10.5.2 South Africa Market CAR T-Cell-Based Drug Forecast &nbsp;10.5.3 Israel Market CAR T-Cell-Based Drug Forecast &nbsp;10.5.4 Turkey Market CAR T-Cell-Based Drug Forecast &nbsp;10.6 Global CAR T-Cell-Based Drug Forecast by Type (2026-2031) &nbsp;10.7 Global CAR T-Cell-Based Drug Forecast by Application (2026-2031) &nbsp;10.7.1 GCC Countries Market CAR T-Cell-Based Drug Forecast 11 Key Players Analysis &nbsp;11.1 Novartis &nbsp;11.1.1 Novartis Company Information &nbsp;11.1.2 Novartis CAR T-Cell-Based Drug Product Offered &nbsp;11.1.3 Novartis CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.1.4 Novartis Main Business Overview &nbsp;11.1.5 Novartis Latest Developments &nbsp;11.2 Gilead Sciences &nbsp;11.2.1 Gilead Sciences Company Information &nbsp;11.2.2 Gilead Sciences CAR T-Cell-Based Drug Product Offered &nbsp;11.2.3 Gilead Sciences CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.2.4 Gilead Sciences Main Business Overview &nbsp;11.2.5 Gilead Sciences Latest Developments &nbsp;11.3 Bristol-Myers Squibb &nbsp;11.3.1 Bristol-Myers Squibb Company Information &nbsp;11.3.2 Bristol-Myers Squibb CAR T-Cell-Based Drug Product Offered &nbsp;11.3.3 Bristol-Myers Squibb CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.3.4 Bristol-Myers Squibb Main Business Overview &nbsp;11.3.5 Bristol-Myers Squibb Latest Developments &nbsp;11.4 J & J &nbsp;11.4.1 J & J Company Information &nbsp;11.4.2 J & J CAR T-Cell-Based Drug Product Offered &nbsp;11.4.3 J & J CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.4.4 J & J Main Business Overview &nbsp;11.4.5 J & J Latest Developments &nbsp;11.5 JW Therapeutics &nbsp;11.5.1 JW Therapeutics Company Information &nbsp;11.5.2 JW Therapeutics CAR T-Cell-Based Drug Product Offered &nbsp;11.5.3 JW Therapeutics CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.5.4 JW Therapeutics Main Business Overview &nbsp;11.5.5 JW Therapeutics Latest Developments &nbsp;11.6 FOSUNKite &nbsp;11.6.1 FOSUNKite Company Information &nbsp;11.6.2 FOSUNKite CAR T-Cell-Based Drug Product Offered &nbsp;11.6.3 FOSUNKite CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.6.4 FOSUNKite Main Business Overview &nbsp;11.6.5 FOSUNKite Latest Developments &nbsp;11.7 CARsgen Therapeutics &nbsp;11.7.1 CARsgen Therapeutics Company Information &nbsp;11.7.2 CARsgen Therapeutics CAR T-Cell-Based Drug Product Offered &nbsp;11.7.3 CARsgen Therapeutics CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.7.4 CARsgen Therapeutics Main Business Overview &nbsp;11.7.5 CARsgen Therapeutics Latest Developments &nbsp;11.8 Autolus Therapeutics &nbsp;11.8.1 Autolus Therapeutics Company Information &nbsp;11.8.2 Autolus Therapeutics CAR T-Cell-Based Drug Product Offered &nbsp;11.8.3 Autolus Therapeutics CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.8.4 Autolus Therapeutics Main Business Overview &nbsp;11.8.5 Autolus Therapeutics Latest Developments &nbsp;11.9 Sorrento Therapeutics &nbsp;11.9.1 Sorrento Therapeutics Company Information &nbsp;11.9.2 Sorrento Therapeutics CAR T-Cell-Based Drug Product Offered &nbsp;11.9.3 Sorrento Therapeutics CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.9.4 Sorrento Therapeutics Main Business Overview &nbsp;11.9.5 Sorrento Therapeutics Latest Developments &nbsp;11.10 Mustang Bio &nbsp;11.10.1 Mustang Bio Company Information &nbsp;11.10.2 Mustang Bio CAR T-Cell-Based Drug Product Offered &nbsp;11.10.3 Mustang Bio CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.10.4 Mustang Bio Main Business Overview &nbsp;11.10.5 Mustang Bio Latest Developments &nbsp;11.11 Bluebird Bio &nbsp;11.11.1 Bluebird Bio Company Information &nbsp;11.11.2 Bluebird Bio CAR T-Cell-Based Drug Product Offered &nbsp;11.11.3 Bluebird Bio CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.11.4 Bluebird Bio Main Business Overview &nbsp;11.11.5 Bluebird Bio Latest Developments &nbsp;11.12 Cellectis &nbsp;11.12.1 Cellectis Company Information &nbsp;11.12.2 Cellectis CAR T-Cell-Based Drug Product Offered &nbsp;11.12.3 Cellectis CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.12.4 Cellectis Main Business Overview &nbsp;11.12.5 Cellectis Latest Developments &nbsp;11.13 Allogene Therapeutics &nbsp;11.13.1 Allogene Therapeutics Company Information &nbsp;11.13.2 Allogene Therapeutics CAR T-Cell-Based Drug Product Offered &nbsp;11.13.3 Allogene Therapeutics CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.13.4 Allogene Therapeutics Main Business Overview &nbsp;11.13.5 Allogene Therapeutics Latest Developments &nbsp;11.14 Celyad &nbsp;11.14.1 Celyad Company Information &nbsp;11.14.2 Celyad CAR T-Cell-Based Drug Product Offered &nbsp;11.14.3 Celyad CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.14.4 Celyad Main Business Overview &nbsp;11.14.5 Celyad Latest Developments 12 Research Findings and Conclusion

Report	Global CAR T-Cell-Based Drug Market Growth (Status and Outlook) 2025-2031
Selected License	Single ID:LPI35831

Buyer Information

Order Summary